APA (7th ed.) Citation

Sachdeva, A., Gillessen, S., Murphy, L., El-Taji, O., Gray, S., Attard, G., . . . Clarke, N. (2025). A0516 – Metabolic benefits of adding metformin to androgen deprivation therapy for patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Results from the STAMPEDE metformin trial. European urology, 87, S1336-S1337. https://doi.org/10.1016/j.eururo.2025.09.3706

Chicago Style (17th ed.) Citation

Sachdeva, A., et al. "A0516 – Metabolic Benefits of Adding Metformin to Androgen Deprivation Therapy for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Results from the STAMPEDE Metformin Trial." European Urology 87 (2025): S1336-S1337. https://doi.org/10.1016/j.eururo.2025.09.3706.

MLA (9th ed.) Citation

Sachdeva, A., et al. "A0516 – Metabolic Benefits of Adding Metformin to Androgen Deprivation Therapy for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Results from the STAMPEDE Metformin Trial." European Urology, vol. 87, 2025, pp. S1336-S1337, https://doi.org/10.1016/j.eururo.2025.09.3706.